Non-Hodgkin's lymphomas clinical practice guidelines in oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 3, 2010, Pages 288-334

  Zelenetz, Andrew D ^a   Abramson, Jeremy S ^a   Advani, Ranjana H ^a   Babis Andreadis, C ^a   Byrd, John C ^a   Czuczman, Myron S ^a   Fayad, Luis ^a   Forero, Andres ^a   Glenn, Martha J ^a   Gockerman, Jon P ^a   Gordon, Leo I ^a   Harris, Nancy Lee ^a   Hoppe, Richard T ^a   Horwitz, Steven M ^a   Kaminski, Mark S ^a   Kim, Youn H ^a   Lacasce, Ann S ^a   Mughal, Tariq I ^a   Nademanee, Auyporn ^a   Porcu, Pierluigi ^a   Press, Oliver ^a   Prosnitz, Leonard ^a   Reddy, Nashitha ^a   Smith, Mitchell R ^a   Sokol, Lubomir ^a   Swinnen, Lode ^a   Vose, Julie M ^a   Wierda, William G ^a   Yahalom, Joachim ^a   Yunus, Furhan ^a   more..

^a NONE

Author keywords

Chronic lymphocytic leukemia; Cutaneous T cell lymphoma; Diagnosis; Diffuse large B cell lymphoma; Follicular lymphoma; Hematopathology; Immunohistochemistry; Lymphoma pathology; Mantle cell lymphoma; Marginal zone lymphoma; Mucosa associated lymphoid tissue lymphoma; Mycosis fungoides; NCCN clinical practice guidelines; Non Hodgkin's lymphoma; Peripheral; S zary syndrome; Staging evaluation; T cell lymphoma; Treatment; Treatment guidelines

Indexed keywords

ASPARAGINASE; CD19 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD45RO ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; IFOSFAMIDE; LEUKOSIALIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR PAX5; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASPIRATION BIOPSY; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER STAGING; CYTOMEGALOVIRUS; FOLLICULAR LYMPHOMA; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOBLASTOMA; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SEZARY SYNDROME; T CELL LYMPHOMA; TUMOR LYSIS SYNDROME; VIRUS REACTIVATION; ARTICLE; CLASSIFICATION; PATHOLOGY;

HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING;

EID: 77949822338     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0021     Document Type: Review

References (142)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-1251.
3. Rappaport H. Tumors of the hematopoietic system. In Lukes RJ, Collins RD. Atlas of Tumor Pathology Series, ed. I. Washington, D.C.: Armed Forces Institute of Pathology; 1966.
4. Hicks EB, Rappaport H, Winter WJ. Follicular lymphoma; a reevaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956;9:792-821.
5. Bennetta MH, Farrer-Brown G, Henry K, et al. Classification of non-Hodgkin's lymphomas. Lancet 1974;2:405-408.
6. Lennert K. Malignant Lymphomas Other Than Hodgkin's Disease. New York: Springer-Verlag; 1978.
7. Lennert K, Feller A. Histopathology of Non-Hodgkin's Lymphomas, 2nd ed. New York: Springer-Verlag; 1992.
8. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982;49:2112-2135.
9. Classification of non-Hodgkin's lymphomas. Reproducibility of major classification systems. NCI non-Hodgkin's Classification Project Writing Committee. Cancer 1985;55:91-95.
10. Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 1994;84:1361-1392.
11. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
12. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795.
13. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
14. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2001.
15. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
16. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008;112:4384-4399.
17. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
18. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446-5456.
19. Katzenberger T, Ott G, Klein T, et al. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol 2004;165:481-490.
20. Hans CP, Weisenburger DD, Vose JM, et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003;101:2363-2367.
21. Cong P, Raffeld M, Teruya-Feldstein J, et al. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 2002;99:3376-3382.
22. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
23. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005;105:3671-3678.
24. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001;19:3602-3610.
25. Willemze R, Meijer CJ, Sentis HJ, et al. Primary cutaneous large cell lymphomas of follicular center cell origin. A clinical follow-up study of nineteen patients. J Am Acad Dermatol 1987;16:518-526.
26. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
27. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502.
28. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
29. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-4594.
30. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930-4935.
31. Ferry JA. Burkitt's lymphoma: clinicoparhologic features and differential diagnosis. Oncologist 2006;11:375-383.
32. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006;354:2431-2442.
33. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006;354:2419-2430.
34. Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999;17:1558-1567.
35. Barth TF, Leirhauser F, Joos S, et al. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol 2002;3:229-234.
36. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-862.
37. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005;29:1411-1421.
38. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinicopathological findings and outcome. Blood 1999;93:2697-2706.
39. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913-3921.
40. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504.
41. Cheson BD, Homing SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-1253.
42. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
43. Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004;22:3046-3052.
44. Meda BA, Buss DH, Woodruff RD, et al. Diagnosis and subclassification of primary and recurrent lymphoma. Am J Clin Pathol 2000;113:688-699.
45. Dong HY, Harris NL, Preffer FI, Pitman MB. Fine-needle aspiration biopsy in the diagnosis and classification of primary and recurrent lymphoma: a retrospective analysis of the utility of cytomorphology and flow cytometry. Mod Pathol 2001;14:472-481.
46. Jeffers M, Milton J, Herriot R, McKean M. Fine needle aspiration cytology in the investigation on non-Hodgkin's lymphoma. J Clin Pathol 1998;51:189-196.
47. Zeppa P, Marino G, Troncone G, Fulciniti F. Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma. Cancer 2004;102:55-65.
48. Dunphy CH. Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. Arch Pathol Lab Med 2004;128:1004-1022.
49. Yang WI, Zukerberg LR, Motokura T, et al. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994;145:86-96.
50. Zukerberg LR, Yang WI, Arnold A, Harris NL. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am J Clin Pathol 1995;103:756-760.
51. Vega F, Medeiros LJ. Chromosomal translocations involved in non-Hodgkin lymphomas. Arch Pathol Lab Med 2003;127:1148-1160.
52. Ohno H, Fukuhara S. Significance of rearrangement of the BCL6 gene in B-cell lymphoid neoplasms. Leuk Lymphoma 1997;27:53-63.
53. Tsuboi K, Iida S, Inagaki H, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000;14:449-456.
54. Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009;27:4211-4216.
55. Willemze R. Primary cutaneous B-cell lymphoma: classification and treatment. Curr Opin Oncol 2006;18:425-431.
56. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999;155:483-492.
57. Howell SJ, Shalet SM. Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep 2002;4:443-452.
58. Conlan M, Bast M, Armitage J, Weisenburger D. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990;8:1163-1172.
59. Lim ST, Tao M, Cheung YB, et al. Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy? Ann Oncol 2005;16:215-218.
60. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:479-484.
61. Senff NJ, Kluin-Nelemans HC, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol 2008;142:52-56.
62. Juneja SK, Wolf MM, Cooper IA. Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma. J Clin Pathol 1990;43:630-632.
63. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3507-3516.
64. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D- glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:1066-1074.
65. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 2006:47:1643-1648.
66. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology 2004;232:823-829.
67. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008;2:152-162.
68. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
69. Targhetta C, Cabras MG, Mamusa AM, et al. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008;93:951-952.
70. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712.
71. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.
72. Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004;83:58-60.
73. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627-629.
74. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749.
75. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-4840.
76. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125-130.
77. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008;2008:450-456.
78. Berentsen S. Rituximab for the treatment of autoimmune cytopenias. Haematologica 2007;92:1589-1596.
79. Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma. Cancer 2004;100:2627-2636.
80. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004.
81. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009;113:2161-2171.
82. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
83. Bussel JB, Kuter DJ, Newland A, et al. Long-term efficacy and safety of romiplostim for the treatment of patients with chronic immune thrombocytopenia (ITP): 5-year update from an open-label extension study [abstract]. Blood 2009;114:Abstract 681.
84. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-2247.
85. D'Arena G, Cascavilla N. Chronic lymphocytic leukemia-associated pure red cell aplasia. Int J Immunopathol Pharmacol 2009;22:279-286.
86. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26:2767-2778.
87. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11.
88. Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitor. JAMA 1965;193:1-6.
89. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98:1048-1054.
90. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAALI (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21:4402-4406.
91. Cortes J, Seiter K, Maziarz RT, et al. Superiority of rasburicase versus allopurinol on serum uric acid control in adult patients with hematological malignancies at risk of developing tumor lysis syndrome: results of a randomized comparative phase III study [abstract]. Blood 2008;112:Abstract 919.
92. Aldoss IT, Weisenburger DD, Fu K, et al. Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park) 2008;22:1508-1517.
93. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004;104:3009-3020.
94. Burmeister T, Schwartz S, Horst HA, et al. Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia 2005;19:1391-1398.
95. Friedberg JW, Ciminello L, Kelly J, et al. Outcome of patients > age 40 with Burkitt lymphoma (BL) treated with aggressive chemorherapeutic regimens: results from the International Burkitt Lymphoma Collaborative Group [abstract]. Blood 2005;106:Abstract928.
96. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14:925-934.
97. Adde M, Shad A, Venzon D, et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 1998;25:33-39; discussion 45-38.
98. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002;13:1264-1274.
99. Lacasce A, Howard O, Lib S, et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004;45:761-767.
100. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461-2470.
101. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004;100:1438-1448.
102. van Imhoff GW, van der Holt B, MacKenzie MA, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005;19:945-952.
103. Kujawski LA, Longo WL, Williams EC, et al. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest 2007;25:87-93.
104. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580.
105. Thomas DA, Kantarjian HM, Cortes J, et al. Long-term outcome after hyper-CVAD and rituximab chemoimmunotherapy for Burkitt (BL) or Burkitt-like (BLL) leukemia/lymphoma and mature b-cell acute lymphocytic leukemia (ALL) [abstract]. Blood 2008;112:Abstract 1929.
106. Hoelzer D. 10th International Conference on Malignant Lymphoma: recent results in the treatment of Burkitt lymphomas [abstract]. Ann Oncol 2008;19(Suppl 4):iv83-84. Abstract 008.
107. Dunleavy K, Little RF, Pittaluga S. 10th International Conference on Malignant Lymphoma: a prospective study of dose-adjusted (DA) EPOCH with rituximab in adults with newly diagnosed Burkitt lymphoma: a regimen with high efficacy and low toxicity [abstract]. Ann Oncol 2008;19:iv83-84. Abstract 009.
108. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/1VAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008;112:2248-2260.
109. Le Gouill S, Lepretre S, Briere J, et al. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia 2003;17:2220-2224.
110. Aljurf M, Zaidi SZ. Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. Biol Blood Marrow Transplant 2005;11:739-754.
111. Larson R, Dodge R, Burns C, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995;85:2025-2037.
112. Hoelzer D, Gokbuget N, Digel W, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002;99:4379-4385.
113. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000;18:547-561.
114. Thomas DA, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004;104:1624-1630.
115. Dabaja BS, Ha CS, Thomas DA, et al. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer 2002;94:2738-2744.
116. Levine JE, Harris RE, Loberiza FR Jr, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 2003;101:2476-2482.
117. Sweetenham JW, Santini G, Qian W, et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 2001;19:2927-2936.
118. Terwey TH, Massenkeil G, Tamm I, et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant 2008;42:791-798.
119. Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood 2000:96:4084-4090.
120. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am 2003;17:673-696.
121. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009;23:2029-2037.
122. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005;23:4372-4380.
123. Nador R, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996;88:645-656.
124. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997:89:1413-1420.
125. Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman's disease in HlV infection: a systematic review of the literature. AIDS Rev 2008;10:25-35.
126. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005;10:412-426.
127. Mounier N, Spina M, Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 2007;136:685-698.
128. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006;107:3832-3840.
129. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19:2171-2178.
130. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Clin Oncol 2004;22:1491-1500.
131. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival - results of the German Multicenter Trial. Cancer 2006;106:1560-1568.
132. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-4659.
133. Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430-4438.
134. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196-1205.
135. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-1543.
136. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-4128.
137. Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008;140:411-419.
138. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005;105:1891-1897.
139. Spina M, Simonelli C, Vaccher E, et al. Long-term follow-up of rituximab and infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in combination with HAART in HIV-related non-Hodgkin's lymphomas (NHL) [abstract]. Blood 2008;112:Abstract 1467.
140. Dunleavy K, Little R, Wayne AS, et al. Long-term outcome of AIDS-related lymphoma treated with abbreviated cycles of EPOCH-RR: a prospective study of 40 patients [abstract]. Blood 2008;112:Abstract 3606.
141. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated, B-cell non-Hodgkin's lymphoma. Blood 2009; in press.
142. Teruya-Feldstein J, Chiao E, Filippa DA, et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 2004;15:1673-1679.